infect
mycobacterium
tuberculosi
remain
major
caus
morbid
mortal
world
sinc
effect
avail
tuberculosi
vaccin
mycobacterium
bovi
bacillu
bcg
suboptim
strong
demand
develop
new
tuberculosi
vaccin
tuberculosi
airborn
diseas
intranas
rout
vaccin
might
prefer
live
influenza
viru
vaccin
might
consid
potenti
vector
mucos
immun
variou
viral
bacteri
pathogen
includ
tuberculosi
gener
sever
subtyp
attenu
recombin
influenza
virus
express
earli
secretori
antigen
target
protein
tuberculosi
read
frame
abl
demonstr
potenc
influenza
viru
ns
vector
induc
tuberculosisspecif
immun
respons
mice
moreov
intranas
immun
mice
guinea
pig
vector
induc
protect
mycobacteri
challeng
similar
induc
bcg
vaccin
sinc
revers
genet
method
develop
negativestrand
rna
virus
influenza
virus
consid
viral
vector
immun
differ
pathogen
influenza
viru
contain
segment
genom
consist
eight
negativestrand
rna
fragment
among
smallest
fragment
ns
encod
two
protein
nep
suitabl
target
genet
manipul
nonstructur
protein
influenza
viru
shown
toler
rel
long
insert
amino
acid
moreov
protein
produc
larg
quantiti
infect
cell
express
foreign
sequenc
read
frame
result
strong
immun
respons
insert
antigen
demonstr
immun
mice
ns
influenza
viru
vector
could
trigger
tcell
respons
especi
two
vector
belong
differ
influenza
viru
subtyp
use
primeboost
immun
howev
influenza
viru
ns
vector
might
less
effici
induct
insertspecif
thelper
antibodi
respons
due
intracellular
local
protein
lead
less
effici
present
link
antigen
major
histocompat
complex
class
ii
pathway
work
test
potenti
recombin
influenza
viru
ns
vector
express
mycobacterium
tuberculosi
antigen
induc
thelper
respons
intranas
immun
mice
accept
control
tuberculosi
infect
depend
recruit
antigenspecif
cell
mainli
cell
lung
releas
cytokin
particularli
gamma
interferon
trigger
bacteriumkil
mechan
activ
macrophag
construct
recombin
influenza
viru
ns
gene
express
earli
secretori
antigen
target
protein
deriv
tuberculosi
introduc
three
differ
antigen
subtyp
influenza
viru
protein
recent
discov
virul
factor
immunodomin
secret
antigen
virul
mycobacteri
strain
howev
absent
mycobacterium
bovi
bacillu
bcg
vaccin
construct
express
fusion
protein
ntermin
amino
acid
residu
influenza
viru
protein
demonstr
ns
vector
could
induc
tuberculosisspecif
respons
intranas
immun
mice
moreov
vaccin
mice
guinea
pig
provid
protect
tuberculosi
equival
provid
bcg
vaccin
vero
mdck
cell
line
origin
american
type
cultur
collect
vero
cell
adapt
cultiv
mixtur
dulbecco
modifi
eagl
medium
dmem
ham
medium
biochrom
mm
lglutamin
proteinfre
supplement
proprietari
formul
polymun
scientif
gmbh
austria
mdck
cell
cultiv
mixtur
dmem
ham
medium
contain
heat
inactiv
fetal
calf
serum
fc
hyclon
mm
lglutamin
virus
influenza
virus
obtain
previous
describ
vero
cell
transfect
use
nucleofect
techniqu
amaxa
accord
manufactur
instruct
plasmid
ppolinshdv
reconstruct
express
protein
insert
foreign
sequenc
read
frame
amino
acid
posit
stop
codon
end
insert
fmd
picornaviru
autocleavag
site
incorpor
sequenc
plasmid
design
ppolinsesathdv
use
togeth
express
plasmid
pa
np
influenza
viru
protein
transfect
vero
cell
twentyfour
hour
later
cell
infect
interferonsensit
helper
viru
carri
fulli
partial
delet
ns
gene
respect
multipl
infect
moi
h
postinfect
u
human
nibsc
first
intern
standard
human
leukocyt
deriv
suspend
rpmi
medium
biochrom
contain
heatinactiv
fetal
calf
serum
mm
lglutamin
per
ml
cultur
medium
ad
cell
incub
h
supernat
passag
twice
vero
cell
presenc
concentr
uml
plaqu
vero
cell
result
viral
vector
subtyp
subtyp
gener
reassort
viru
mouseadapt
strain
viral
gene
control
revers
transcriptionpcr
correct
sequenc
modifi
ns
gene
confirm
nucleotid
sequenc
analysi
apuerto
use
wildtyp
wt
parent
strain
virus
grown
plaqu
vero
cell
co
sodium
dodecyl
sulfatepolyacrylamid
gel
electrophoresi
western
blot
analysi
vero
cell
infect
recombin
virus
moi
without
addit
trypsin
h
lyse
mper
lysi
buffer
pierc
contain
mm
edta
proteas
inhibitor
pierc
protein
separ
gradient
trisglycin
gel
anam
use
trisglycin
buffer
system
western
blot
perform
electrophoret
transfer
protein
gel
polyvinyl
difluorid
membran
millipor
hour
blot
incub
antim
tuberculosi
mous
monoclon
antibodi
antibodyshop
dilut
phosphatebuff
salin
pb
tween
skim
milk
serva
wash
membran
incub
antimous
alkalin
phosphatas
sigma
dilut
pb
tween
skim
milk
serva
blot
develop
stain
buffer
mm
tri
hcl
mm
nacl
mm
mgcl
ph
nitroblu
tetrazolium
immunofluoresc
vero
cell
infect
recombin
flu
virus
moi
h
postinfect
cell
fix
paraformaldehyd
incub
rabbit
polyclon
fusion
antibodi
follow
incub
fluorescein
isothiocyanateconjug
goat
antirabbit
immunoglobulin
g
sigma
fluoresc
visual
uv
confoc
microscop
biorad
anim
mice
week
old
use
replic
studi
enzymelink
immunospot
elispot
assay
enzymelink
immunosorb
assay
elisa
obtain
charl
river
laboratori
germani
challeng
studi
mice
week
old
outbr
hartley
guinea
pig
g
purchas
lab
anim
nurseri
st
petersburg
russia
anim
free
access
water
standard
rodent
chow
viru
replic
mous
lung
mice
infect
intranas
pfuanim
viru
narcosi
day
mice
sacrif
lung
asept
remov
tissu
extract
pb
prepar
grind
tissu
sampl
rotor
homogen
suspens
centrifug
g
minut
viral
yield
supernat
determin
limitingdilut
assay
vero
cell
elispot
assay
tcell
respons
mice
determin
day
second
immun
spleen
collect
mechan
dissoci
singlecel
suspens
mean
cell
strainer
falcon
erythrocyt
present
cell
suspens
lyse
trisbuff
ammonium
chlorid
splenocyt
wash
resuspend
dmem
contain
fc
penicillin
streptomycin
uml
one
hundr
microlit
cell
suspens
cellsml
ad
microtit
plate
nitrocellulos
base
millipor
precoat
gml
bd
pharmingen
cell
incub
h
co
dmem
contain
fc
uml
penicillin
streptomycin
either
presenc
absenc
recombin
protein
gml
fusion
antibodi
esat
synthet
peptid
compris
b
restrict
epitop
biotinyl
monoclon
antibodi
bd
pharmingen
util
conjug
plate
incub
streptavidin
peroxidas
roch
spot
repres
cell
develop
util
substrat
sigma
contain
hydrogen
peroxid
sodium
acet
ph
spot
count
help
dissect
microscop
result
express
mean
number
spotform
cell
standard
error
mean
duplic
cultur
elisa
modifi
elisa
protocol
perform
briefli
recombin
protein
gml
fusion
antibodi
use
coat
antigen
serial
dilut
pool
blood
sera
pb
contain
skim
milk
serva
ad
coat
plate
mixtur
incub
h
room
temperatur
bound
antibodi
detect
goat
antimous
immunoglobulin
g
conjug
horseradish
peroxidas
zyme
plate
stain
tmb
fermenta
substrat
absorb
measur
nm
cutoff
valu
defin
mean
absorpt
valu
neg
control
sera
plu
two
standard
deviat
bacteri
strain
virul
mycobacterium
bovi
bovi
bovinu
tuberculosi
grown
lowensteinjensen
medium
second
gener
mycobacteri
cultur
week
use
experiment
infect
protect
studi
mice
mice
divid
four
group
contain
anim
first
group
mice
immun
twice
without
narcosi
viru
vector
pfumous
week
apart
second
group
receiv
two
dose
wt
influenza
viru
dose
pfumous
week
apart
third
group
mice
immun
cfuanim
bovi
bcg
strain
pasteur
time
initi
immun
control
group
mice
immun
pb
six
week
first
immun
anim
challeng
via
later
tail
vein
cfu
virul
bovi
suspend
pb
volum
ml
anim
sacrif
day
postchalleng
investig
histopatholgi
lung
remov
fix
formalin
ph
embed
paraffin
histopatholog
studi
section
stain
hematoxylin
eosin
elisa
cell
spleen
mediastin
thorac
lymph
node
mln
remov
cytokin
determin
cell
adjust
concentr
cellsml
rpmi
medium
fetal
calf
serum
mm
lglutamin
gml
gentamicin
sigma
one
hundr
microlit
cell
suspens
ad
cell
cultur
plate
cytokin
product
induc
fusion
antibodi
concentr
gml
concanavalin
cona
sigma
concentr
gml
use
posit
control
cell
viabil
cell
incub
h
co
assay
use
supernat
conastimul
cell
perform
quantikin
elisa
kit
r
system
inc
accord
manufactur
protocol
briefli
plate
coat
monoclon
antibodi
block
standard
sampl
ad
plate
incub
room
temperatur
incub
secondari
antibodi
colorimetr
substrat
ad
min
reaction
termin
plate
read
nm
use
multipl
reader
multiscan
biorad
bacteri
load
five
anim
group
check
quantiti
viabl
bacteria
lung
spleen
purpos
tissu
homogen
cultur
solid
lowensteinjensen
medium
bacteri
coloni
count
week
incub
data
express
log
mean
number
bacteria
recov
per
organ
guinea
pig
protect
studi
guinea
pig
immun
group
four
twice
week
either
subcutan
sc
left
inguin
region
trival
vaccin
contain
mixtur
flu
vector
one
dose
bcg
bacilli
inject
sc
left
inguin
region
time
first
immun
addit
group
pbsimmun
anim
use
control
six
week
first
immun
anim
challeng
cfu
tuberculosi
administ
sc
right
inguin
region
anim
weigh
weekli
observ
period
nine
week
challeng
one
anim
four
control
group
die
sever
tuberculosi
anim
sacrif
bacteri
load
lung
spleen
determin
nonparametr
mannwhitney
test
use
compar
log
cfu
bacteri
count
across
immun
group
three
differ
subtyp
recombin
influenza
virus
express
protein
tuberculosi
obtain
revers
genet
method
describ
previous
recombin
virus
design
recombin
virus
grew
high
titer
vero
mdck
cell
genet
stabil
recombin
virus
confirm
five
passag
mdck
cell
western
blot
use
monovol
influenza
viru
vector
protect
tuberculosi
clonal
antibodi
specif
protein
data
shown
western
blot
analysi
lysat
vero
cell
infect
recombin
vector
use
monoclon
antibodi
reveal
presenc
two
band
correspond
fusion
protein
kda
one
smaller
form
approxim
kda
fig
lower
band
persist
sever
western
blot
experi
therefor
could
attribut
posttransl
cleavag
fusion
protein
natur
modif
remain
studi
howev
cleavag
like
mediat
incorpor
cleavag
site
sinc
inact
due
point
mutat
detect
nucleotid
sequenc
analysi
rescu
virus
result
intracellular
distribut
fusion
protein
infect
cell
confin
mainli
nuclei
fig
similar
normal
local
influenza
viru
protein
h
postinfect
replic
mous
lung
previou
studi
shown
similar
influenza
viru
ns
vector
includ
human
immunodefici
viru
type
nef
sequenc
replic
defici
mice
contrast
virus
capabl
replic
mous
lung
rang
logg
peak
replic
curv
day
infect
nevertheless
three
vector
could
defin
attenu
sinc
lung
patholog
bodi
weight
decreas
could
detect
anim
data
shown
influenza
viru
vector
induc
tcell
respons
mice
sever
group
mice
infect
twice
interv
differ
combin
viral
vector
indic
fig
anoth
group
mice
immun
twice
trival
vaccin
contain
three
subtyp
ten
day
second
immun
suspens
splenocyt
stimul
protein
peptid
compris
brestrict
epitop
number
cell
assess
elispot
assay
group
immun
anim
develop
respons
data
present
fig
also
show
prime
monoval
vaccin
boost
anoth
subtyp
effici
induct
thelper
cell
immun
trival
vaccin
time
antibodi
respons
protein
achiev
immun
protocol
elisa
data
shown
mous
protect
studi
protect
efficaci
influenza
viru
ns
vector
assess
doubl
immun
mice
interv
vector
control
group
receiv
wt
convent
bcg
vaccin
three
week
second
immun
mice
challeng
intraven
iv
virul
bovi
anim
examin
day
postchalleng
histopatholog
symptom
lung
develop
immun
respons
bacteri
count
lung
spleen
histopatholog
histolog
examin
lung
nonvaccin
anim
reveal
intens
larg
inflamm
foci
mice
lung
lesion
contain
larg
number
degrad
neutrophil
nuclear
debri
larg
necrot
foci
surround
conglomer
destroy
cell
found
mice
fig
c
contrast
patholog
chang
lung
vaccin
anim
less
pronounc
infiltr
foci
discret
small
fill
macrophag
lymphocyt
singl
epithelioid
cell
fig
respons
challeng
shown
fig
splenocyt
mice
vaccin
influenza
viru
vector
significantli
better
produc
respons
antigen
nonvaccin
anim
howev
splenocyt
mice
vaccin
bcg
wt
display
almost
pattern
releas
group
immun
influenza
viru
vector
reactiv
splenocyt
cona
deriv
non
march
guest
http
cviasmorg
vaccin
influenza
viru
control
group
substanti
diminish
indic
possibl
immunolog
exhaust
due
tuberculosi
process
differ
pictur
observ
lymphocyt
popul
deriv
mln
fig
lymphocyt
nonvaccin
challeng
anim
respond
stimul
detect
level
mice
vaccin
bcg
wt
well
anim
poor
respons
ngml
lymphocyt
mice
immun
vector
produc
increas
amount
ngml
bacteri
load
immunolog
histolog
data
appear
correl
bacteri
count
result
lung
spleen
tabl
immun
flu
vector
result
statist
signific
reduct
bacteri
number
lung
bacteri
load
reduct
spleen
compar
nonvaccin
infect
control
mice
level
protect
induc
vaccin
recombin
influenza
virus
compar
bcg
vaccin
reduct
bacteri
number
lung
reduct
spleen
immun
wt
influenza
viru
trigger
inhibitori
effect
bacteri
growth
mous
organ
guinea
pig
protect
studi
encourag
data
mous
experi
evalu
potenc
viral
vector
vaccin
guinea
pig
model
appropri
human
tuberculosi
take
account
guinea
pig
rel
resist
influenza
viru
infect
sc
rout
immun
use
addit
applic
differ
group
four
guinea
pig
immun
twice
fluesat
vector
inocul
bcg
pb
six
week
first
immun
anim
challeng
sc
tuberculosi
nine
week
challeng
one
four
guinea
pig
control
group
die
sever
tuberculosi
wherea
vaccin
anim
progress
gain
weight
fig
bacteri
titer
lung
spleen
anim
immun
bcg
vector
significantli
reduc
log
respect
lung
log
respect
spleen
compar
nonvaccin
control
fig
interestingli
bacteri
reduct
spleen
achiev
sc
vaccin
log
vector
superior
achiev
rout
vaccin
log
least
effect
bcg
vaccin
tuberculosi
remain
one
virul
diseas
worldwid
contrast
potenti
danger
respira
tuberculosi
becam
even
seriou
due
unfortun
synergi
human
immunodefici
viru
infect
appear
multidrugresist
form
tubercl
bacteria
vaccin
world
wide
use
vaccin
mycobacterium
bovi
bcg
vari
protect
efficaci
depend
geograph
region
urgent
need
develop
new
effect
tuberculosi
vaccin
studi
anim
model
human
demonstr
control
tuberculosi
infect
could
attribut
wide
rang
immun
compon
includ
subset
cell
cytokin
macrophag
role
may
vari
acut
chronic
infect
howev
commonli
accept
main
effector
cell
strong
evid
mucos
immun
respiratori
tract
like
intranas
applic
bcg
vaccin
adenovirusbas
vaccin
express
tuberculosi
antigen
could
advantag
system
rout
immun
tuberculosi
anoth
trend
vaccin
develop
includ
immun
newli
discov
tuberculosi
antigen
absent
current
bcg
vaccin
shown
one
import
reason
attenu
bcg
vaccin
delet
genom
region
encod
sever
protein
requir
cytolysi
bacteri
spread
among
protein
shown
enhanc
permeabl
artifici
membran
suggest
possibl
direct
role
cytolysi
infect
macrophag
allow
mycobacterium
spread
cell
protein
secret
mycobacteria
earli
stage
tuberculosi
infect
accomplish
function
heterodim
togeth
anoth
cultur
filtrat
protein
cultur
filtrat
protein
importantli
protein
well
earli
secret
antigen
appear
potent
immunogen
induc
immun
respons
anim
well
human
success
immun
protein
anim
depend
method
deliveri
protein
fail
induc
signific
protect
immun
respons
peptid
dna
vaccin
vaccin
use
live
bacteri
vector
bovi
bcg
salmonella
enterica
serovar
typhimurium
express
induc
protect
immun
respons
mice
current
studi
construct
influenza
viru
ns
vector
express
protein
test
potenc
induc
immun
respons
provid
protect
tuberculosi
besid
advantag
associ
intranas
applic
develop
local
immun
respons
respiratori
tract
influenza
viru
vector
ideal
tool
primeboost
immun
sinc
sever
noncrossreact
subtyp
influenza
virus
avail
experi
protein
deliv
respiratori
tract
use
vector
util
primeboost
strategi
vari
subtyp
doubl
immun
trival
vaccin
vector
design
attenu
virus
mean
truncat
gene
interestingli
previous
obtain
recombin
influenza
virus
express
nef
green
fluoresc
protein
insert
posit
open
read
frame
replic
defici
mice
presum
due
inappropri
function
protein
case
fig
mean
weight
gain
guinea
pig
two
group
anim
immun
twice
trival
vaccin
sc
respect
one
group
guinea
pig
immun
bcg
sc
time
first
immun
guinea
pig
use
control
group
six
week
first
immun
anim
challeng
sc
tuberculosi
weigh
weekli
time
point
repres
mean
weight
gain
four
guinea
pig
error
bar
indic
standard
error
mean
hand
protein
alon
might
promot
dimer
protein
construct
presum
lead
increas
stabil
immunogen
foreign
antigen
found
vector
capabl
induc
substanti
thelper
respons
despit
fact
fusion
protein
secret
infect
cell
incorpor
viru
particl
effect
presum
due
crossprim
mechan
antigen
present
illustr
high
vaccin
potenti
influenza
viru
ns
vector
vaccin
mice
result
increas
respons
antigen
challeng
lymphocyt
deriv
mln
splenocyt
mention
experi
efficaci
vaccin
test
use
iv
challeng
model
demonstr
vaccin
even
system
challeng
high
dose
mycobacteria
provid
substanti
level
protect
compar
bcg
vaccin
measur
product
thelper
cell
deriv
spleen
mice
vaccin
bcg
wt
show
almost
pattern
releas
group
immun
influenza
viru
vector
contrast
respons
stimul
splenocyt
mice
immun
influenza
viru
vector
stimul
concanavalin
show
signific
increas
product
indic
better
condit
immun
system
mice
titrat
bacteri
load
spleen
lung
clearli
demonstr
immun
although
provid
system
immun
respons
tuberculosi
especi
effect
protect
lung
importantli
immunolog
data
full
correl
bacteri
count
result
histolog
examin
lung
tissu
protect
effect
vaccin
also
signific
guinea
pig
gener
accept
suitabl
model
tuberculosi
vaccin
guinea
pig
rel
resist
influenza
viru
infect
anim
vaccin
sc
vector
show
higher
resist
sc
tuberculosi
challeng
anim
applic
would
appear
sc
immun
induc
better
immun
system
level
reflect
signific
reduct
bacteri
titer
spleen
lung
mechan
antigen
present
sc
applic
live
influenza
viru
vector
remain
elucid
howev
preliminari
result
show
virus
capabl
infect
macrophag
presum
antigenpres
cell
involv
dermal
immun
system
lower
effici
immun
guinea
pig
could
also
attribut
low
sensit
anim
influenza
viru
infect
nevertheless
result
anim
protect
studi
reveal
effect
vector
similar
convent
bcg
vaccin
result
current
work
provid
first
evid
potenc
influenza
viru
vector
express
tuberculosi
antigen
use
prophylaxi
sinc
live
influenza
viru
vaccin
licens
use
children
adult
flumist
ns
gene
could
engin
express
addit
antigen
deriv
pathogen
due
seriou
threat
tuberculosi
infect
worldwid
mycobacteri
antigen
consid
import
target
incorpor
recombin
influenza
viru
vaccin
administr
